cagrilintide results In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial Cagrilintide, Tirzepatide, and Retatrutide Peptides:
Description
Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe
Lyophilized peptides tolerate freezing without damage
Feeling uncertain is completely normal
Store at room temperature and protect from light
I would likely have experienced neurological damage with that treatment
People report decreased appetite as early as one week, and significantly less hunger, reduced eating, and fewer cravings starting between weeks 3 and 8
